2019
Interventional oncology: aiming globally to be the 4 th pillar of cancer care
Madoff DC, Chapiro J, Pua U. Interventional oncology: aiming globally to be the 4 th pillar of cancer care. Chinese Clinical Oncology 2019, 8: 56. PMID: 31968980, DOI: 10.21037/cco.2019.12.12.Peer-Reviewed Original ResearchConceptsIO therapyInterventional oncologyClinical OncologyNational Comprehensive Cancer NetworkComprehensive Cancer NetworkDisease treatment guidelinesOncologic patient managementOncologic communityPalliative settingTreatment guidelinesOncologic careInterventional oncologistsMedical oncologyCancer careClinical trialsTreatment strategiesPatient managementPatient allocationCancer NetworkInterventional radiologyOncologyTherapyEuropean SocietyRadiation oncologyAmerican SocietyImmunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper
Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper. Radiology 2019, 292: 25-34. PMID: 31012818, PMCID: PMC6604797, DOI: 10.1148/radiol.2019182326.Peer-Reviewed Original ResearchConceptsInterventional oncologyCancer management planCancer-related problemsInterventional oncologistsTreatment of cancerCancer patientsImmuno-oncologyInvasive proceduresInterventional radiologyRadiation oncologyOncologyImage guidanceCancerCancer researchSubspecialty fieldsPivotal roleImmunotherapyPatientsOncologistsDiagnosisCare
2016
Interventional Oncology in Hepatocellular Carcinoma
Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma. The Cancer Journal 2016, 22: 365-372. PMID: 27870678, PMCID: PMC5125535, DOI: 10.1097/ppo.0000000000000227.Peer-Reviewed Original ResearchConceptsInterventional oncologyLocoregional therapyHepatocellular carcinomaInterdisciplinary clinical practiceTumor response assessmentOngoing clinical trialsComplex clinical problemImmune response pathwaysTransarterial chemoembolizationCancer careCombination therapyClinical managementClinical trialsRadiofrequency ablationResponse assessmentSystemic effectsClinical problemClinical practiceEmbolic materialTherapyCancer treatmentIntraprocedural imagingOncologyRadiation oncologyCarcinomaIrreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go
Savic LJ, Chapiro J, Hamm B, Gebauer B, Collettini F. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. RöFo 2016, 188: 735-745. PMID: 27074423, DOI: 10.1055/s-0042-104203.Peer-Reviewed Original ResearchConceptsClinical evidenceIrreversible electroporationInterventional oncologyPancreatic irreversible electroporationSite-specific complicationsAvailable clinical evidenceUse of IRELimited clinical evidenceFavorable safety profileTolerable morbidityOncologic efficacyPreclinical findingsBile ductSafety profileNeurovascular bundleInvasive treatmentLung parenchymaAblation therapySolid tumorsClinical settingTumor ablation therapyHeat sink effectNon-thermal fashionLiverTumor ablation
2015
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions
Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal Of Radiology 2015, 88: 20140564. PMID: 25978585, PMCID: PMC4651391, DOI: 10.1259/bjr.20140564.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticCombined Modality TherapyDiffusion of InnovationEmbolization, TherapeuticFemaleForecastingHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMicrospheresNiacinamidePatient SelectionPhenylurea CompoundsRadiopharmaceuticalsSorafenibYttrium RadioisotopesConceptsIntra-arterial therapyHepatocellular carcinomaSecondary liver malignanciesManagement of patientsHealthy liver tissueLocoregional therapyLiver malignanciesClinical rationaleHigh doseInterventional oncologySystematic reviewAnticancer treatmentLiver tissueInvasive natureClinical achievementsChemoresistant cancersTherapyMedical communityPatientsCarcinomaTreatmentPivotal roleMalignancySorafenibCancer